Discovery of Potent 3,5-Diphenyl-1,2,4-oxadiazole Sphingosine-1-phosphate-1 (S1P1) Receptor Agonists with Exceptional Selectivity against S1P2 and S1P3
摘要:
A class of 3,5-diphenyl-1,2,4-oxadiazole based compounds have been identified as potent sphingosine-1-phosphate-1 (S1P(1)) receptor agonists with minimal affinity for the S1P(2) and S1P3 receptor subtypes. Analogue 26 (S1P(1) IC50 = 0.6 nM) has an excellent pharmacokinetics profile in the rat and dog and is efficacious in a rat skin transplant model, indicating that S1P(3) receptor agonism is not a component of inummosuppressive efficacy.
Antibacterial compounds of formula (I) are provided:
as well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of such compounds.
Shabarov,Yu.S. et al., Journal of general chemistry of the USSR, 1961, vol. 31, p. 1693 - 1697
作者:Shabarov,Yu.S. et al.
DOI:——
日期:——
Discovery of Potent 3,5-Diphenyl-1,2,4-oxadiazole Sphingosine-1-phosphate-1 (S1P<sub>1</sub>) Receptor Agonists with Exceptional Selectivity against S1P<sub>2</sub> and S1P<sub>3</sub>
作者:Zhen Li、Weirong Chen、Jeffrey J. Hale、Christopher L. Lynch、Sander G. Mills、Richard Hajdu、Carol Ann Keohane、Mark J. Rosenbach、James A. Milligan、Gan-Ju Shei、Gary Chrebet、Stephen A. Parent、James Bergstrom、Deborah Card、Michael Forrest、Elizabeth J. Quackenbush、L. Alexandra Wickham、Hugo Vargas、Rose M. Evans、Hugh Rosen、Suzanne Mandala
DOI:10.1021/jm0503244
日期:2005.10.1
A class of 3,5-diphenyl-1,2,4-oxadiazole based compounds have been identified as potent sphingosine-1-phosphate-1 (S1P(1)) receptor agonists with minimal affinity for the S1P(2) and S1P3 receptor subtypes. Analogue 26 (S1P(1) IC50 = 0.6 nM) has an excellent pharmacokinetics profile in the rat and dog and is efficacious in a rat skin transplant model, indicating that S1P(3) receptor agonism is not a component of inummosuppressive efficacy.